Yohann Loriot

Q: What Schools Are Affiliated With Yohann Loriot

Yohann Loriot is affiliated with the following schools: Paris-Saclay University, University of Alberta, University of British Columbia, Paris Diderot University

Yohann Loriot's AcademicInfluence.com Rankings

Yohann Loriot

Philosophy

#9000

World Rank

#12490

Historical Rank

Logic

#6008

World Rank

#7481

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Yohann Loriot's Degrees

PhD Biomedical Sciences Université Paris Cité

Why Is Yohann Loriot Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yohann Loriot's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Abiraterone and increased survival in metastatic prostate cancer. (2011) (3933)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (2018) (3049)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial (2016) (2837)
TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells (2018) (2552)
Enzalutamide in metastatic prostate cancer before chemotherapy. (2014) (2357)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014) (2071)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (2017) (1477)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (2018) (961)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. (2019) (655)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. (2020) (486)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. (2017) (465)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). (2013) (293)
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. (2017) (277)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. (2015) (262)
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. (2021) (246)
Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study. (2010) (198)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. (2020) (191)
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. (2015) (176)
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies (2013) (175)
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. (2015) (171)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. (2021) (164)
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. (2009) (162)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study (2019) (156)
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study (2017) (139)
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors (2021) (128)
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. (2015) (114)
Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment (2018) (114)
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities (2017) (112)
Carcinomas of an unknown primary origin—diagnosis and treatment (2011) (111)
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth (2015) (108)
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers (2016) (108)
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. (2019) (108)
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). (2014) (105)
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. (2019) (100)
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study (2018) (99)
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (95)
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. (2010) (92)
Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. (2014) (88)
Are RAS mutations predictive markers of resistance to standard chemotherapy? (2009) (82)
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression (2021) (81)
BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP†. (2021) (79)
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). (2018) (77)
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. (2014) (75)
High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. (2015) (74)
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. (2016) (73)
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. (2020) (73)
2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (72)
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. (2009) (72)
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. (2015) (72)
Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy (2008) (72)
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer (2016) (70)
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). (2015) (66)
Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. (2015) (65)
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. (2021) (65)
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL (2017) (65)
Differential expression of biomarkers in men and women. (2009) (64)
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors (2019) (61)
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). (2016) (61)
Who dies from prostate cancer? (2014) (59)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer (2015) (58)
LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 (2020) (57)
Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap) (2018) (55)
Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. (2019) (54)
Targeted therapy-induced radiation recall. (2013) (52)
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. (2016) (50)
Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination (2010) (49)
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. (2019) (49)
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) (49)
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. (2015) (48)
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. (2015) (48)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). (2013) (47)
Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer (2015) (46)
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients (2017) (45)
Novel therapeutic targets in advanced urothelial carcinoma. (2016) (45)
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study (2014) (45)
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model (2020) (44)
Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells (2011) (43)
Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. (2016) (43)
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors (2013) (42)
Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). (2018) (42)
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. (2010) (40)
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. (2013) (40)
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial (2018) (40)
Systemic treatments for high-risk localized prostate cancer (2018) (40)
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. (2017) (40)
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. (2020) (40)
IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy (2013) (39)
Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials (2017) (39)
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? (2010) (39)
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. (2019) (38)
Enzalutamide in castration‐resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial (2017) (36)
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial (2021) (36)
Lung Cancer Stem Cell: New Insights on Experimental Models and Preclinical Data (2010) (36)
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. (2021) (36)
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. (2017) (36)
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). (2016) (36)
Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer (2014) (35)
Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. (2015) (35)
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. (2015) (34)
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study (2016) (34)
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study (2022) (34)
Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. (2012) (34)
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial (2019) (33)
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study (2021) (33)
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing. (2018) (33)
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. (2016) (33)
Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study. (2018) (33)
Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. (2017) (32)
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. (2012) (32)
Genitourinary tumors, non-prostate (2012) (31)
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. (2016) (31)
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study (2021) (29)
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. (2018) (29)
Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. (2014) (28)
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. (2013) (28)
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis (2016) (27)
Method for semi-automated microscopy of filtration-enriched circulating tumor cells (2016) (27)
An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. (2020) (27)
Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. (2012) (27)
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. (2009) (26)
Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. (2013) (26)
Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy (2009) (26)
BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation (2010) (26)
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. (2020) (26)
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. (2012) (25)
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. (2020) (25)
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. (2008) (25)
Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy (2019) (24)
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. (2017) (24)
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (2019) (23)
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration‐resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial (2017) (23)
Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic (2020) (23)
Identifying the Primary Site Using Gene Expression Profiling in Patients with Carcinoma of an Unknown Primary (CUP): A Feasibility Study from the GEFCAPI (2012) (23)
Efficacy of docetaxel chemotherapy in metastatic prostate cancer (mPC) patients (pts) experiencing early castration resistance (CR). (2013) (23)
Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. (2010) (22)
Role of Checkpoint Inhibition in Localized Bladder Cancer. (2018) (22)
How to select targeted therapy in renal cell cancer. (2010) (22)
Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. (2019) (21)
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial (2017) (21)
Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial. (2020) (21)
Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. (2020) (21)
ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001. (2020) (20)
Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) Survey. (2010) (20)
Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. (2013) (20)
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) (2021) (20)
Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study (2016) (19)
Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study (2016) (19)
Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. (2016) (19)
Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. (2015) (19)
Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. (2021) (19)
Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study. (2020) (19)
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer (2017) (19)
LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI) (2020) (19)
702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study (2020) (18)
Minimal residual disease in solid neoplasia: New frontier or red-herring? (2012) (18)
Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors (2010) (18)
Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. (2012) (17)
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. (2017) (16)
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen. (2018) (16)
EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. (2021) (16)
Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients (2014) (16)
Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. (2021) (16)
Novel and bone-targeted agents for CRPC. (2012) (16)
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort (2017) (15)
Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. (2017) (15)
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. (2017) (15)
A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). (2017) (15)
KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). (2021) (15)
Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study. (2015) (15)
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) (2015) (15)
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology (2022) (15)
697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) (2020) (15)
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). (2019) (14)
Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). (2013) (14)
Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy. (2020) (14)
21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210) (2015) (14)
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone (2016) (14)
TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. (2021) (14)
Management of non-metastatic castrate-resistant prostate cancer: A systematic review. (2018) (14)
Is there a withdrawal syndrome with abiraterone acetate (AA)? (2013) (14)
Taxanes: still a major weapon in the armamentarium against prostate cancer. (2013) (14)
1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) (2017) (14)
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. (2020) (13)
TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. (2022) (13)
Pemetrexed-induced pneumonitis: a case report. (2009) (13)
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer (2020) (13)
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG. (2018) (13)
704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 (2020) (12)
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities. (2021) (12)
Reponse to Cabazitaxel in the Postchemotherapy Setting in Crpc Patients Previously Treated with Docetaxel and Abiraterone Acetate (2012) (12)
Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. (2015) (12)
Lymphadenectomy for Upper Tract Urothelial Carcinoma: A Systematic Review (2019) (12)
808OINHIBITION OF PD-L1 BY MPDL3280A LEADS TO CLINICAL ACTIVITY IN PTS WITH METASTATIC UROTHELIAL BLADDER CANCER (UBC). (2014) (12)
Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100. (2012) (12)
Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). (2014) (11)
Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations. (2020) (11)
699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers (2020) (11)
Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. (2017) (11)
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report (2020) (11)
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. (2022) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study (2021) (10)
A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy. (2020) (10)
Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer (2018) (10)
TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. (2019) (10)
Safety of available treatment options for renal cell carcinoma (2016) (10)
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance. (2021) (9)
BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know? (2021) (9)
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. (2022) (9)
7049 POSTER Management of Metastatic Castration-resistant Prostate Cancer (mCRPC) After an Initial Good Response to First-line Docetaxel (D) -a Retrospective Study on 270 Patients (pts) (2011) (9)
Atezolizumab in urothelial bladder carcinoma. (2018) (9)
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. (2019) (9)
Impact of enzalutamide, an androgen receptor (AR) signalling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study (2012) (9)
How to select amongst available options for the treatment of advanced RCC? (2012) (9)
Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC). (2019) (9)
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. (2021) (9)
[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma]. (2017) (9)
First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. (2015) (9)
The SEMITEP trial: De-escalating chemotherapy in low-volume metastatic seminoma based on early FDG-PET. (2020) (8)
Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM). (2022) (8)
Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial. (2017) (8)
Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer (2018) (8)
Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. (2016) (8)
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. (2020) (8)
IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC) (2016) (8)
Everolimus Versus Axitinib as Second‐line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy (2017) (8)
Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study. (2018) (8)
Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic (2018) (8)
699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1) (2021) (8)
709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study (2020) (8)
Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. (2020) (8)
LBA24 Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study (2021) (8)
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer (2020) (7)
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples (2014) (7)
Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC). (2019) (7)
Towards random sequencing or precision medicine in castration-resistant prostate cancer? (2014) (7)
8O_PRTGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma (2017) (7)
765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL. (2014) (7)
WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. (2018) (7)
752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations (2020) (7)
ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). (2019) (7)
Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC). (2019) (7)
Durvalumab in urothelial cancers (2018) (7)
Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy. (2012) (7)
746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors (2020) (7)
KEYNOTE-361: Phase 3 trial of pembrolizumab ± chemotherapy versus chemotherapy alone in advanced urothelial cancer (2018) (7)
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer (2022) (7)
Immunodynamics of explanted human tumors for immuno‐oncology (2020) (6)
Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy. (2017) (6)
767PRESPONSE RATES AND OUTCOMES WITH ENZALUTAMIDE FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER AND VISCERAL DISEASE IN THE PREVAIL TRIAL. (2014) (6)
1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361. (2021) (6)
Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (2014) (6)
700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC) (2021) (6)
Expanding role of chemotherapy in lung cancer. (2006) (6)
Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer (2019) (6)
Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer. (2015) (6)
Prognosis of renal cell carcinoma with bone metastases: Experience in 300 consecutive patients. (2017) (6)
Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. (2022) (5)
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. (2021) (5)
796TiP TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy (2020) (5)
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial. (2021) (5)
False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. (2013) (5)
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy. (2021) (5)
FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC. (2010) (5)
Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study (2012) (5)
Detection of additional occult malignancy though profiling of ctDNA in late-stage cancer patients. (2021) (5)
Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer (2015) (5)
Stem Cell Tracking: Toward Clinical Application in Oncology? (2012) (5)
The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle? (2020) (5)
Wound healing delay after central venous access following DCF/VEGF-trap therapy (2009) (5)
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. (2020) (5)
Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. (2020) (5)
Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. (2021) (5)
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. (2020) (5)
Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results. (2015) (4)
MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (2018) (4)
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study (2021) (4)
2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial. (2010) (4)
Association between lymphoma and melanoma: report of a single-center series of eight patients and a review of the literature (2006) (4)
A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results. (2013) (4)
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma (2022) (4)
Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC). (2019) (4)
[Cancer in Africa, a new health challenge. Examples of Mali and OncoMali]. (2010) (4)
A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress (2019) (4)
Whole-exome sequencing of single circulating tumor cells is a useful tool for studying the intrapatient genetic heterogeneity in metastatic prostate cancer. (2017) (4)
Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. (2014) (4)
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy (2021) (4)
919TiPPembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial (2017) (4)
Enzalutamide and sleep apnea: an emerging central nervous system side-effect? (2016) (4)
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations. (2020) (4)
Effect of everolimus therapy on skeletal muscle wasting in patients with metastatic renal cell carcinoma (mRCC): Results from a placebo-controlled study. (2011) (4)
Fibroblast growth factor receptors across urothelial carcinoma landscape. (2020) (4)
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy (2020) (4)
Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma (2019) (4)
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. (2020) (4)
MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer (2019) (4)
TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC). (2022) (3)
Internet to boost patient accrual in oncology trials? A multiinstitutional AERIO study. (2011) (3)
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. (2022) (3)
Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC) (2019) (3)
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. (2022) (3)
Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC). (2019) (3)
PI-05 LATE-BREAKING ABSTRACT: THE PREVAIL STUDY: PRIMARY AND NON-VISCERAL / VISCERAL DISEASE SUBGROUP RESULTS FOR ENZALUTAMIDE-TREATED MEN WITH METASTATIC PROSTATE CANCER (MPC) THAT HAD PROGRESSED ON ADT (2014) (3)
ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC). (2019) (3)
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). (2022) (3)
Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future. (2020) (3)
796PEARLY PSA RESPONSE IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH MCRPC TREATED WITH NEXT-GENERATION ANDROGEN PATHWAY INHIBITORS. (2014) (3)
EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma (2019) (3)
Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma. (2022) (3)
Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02. (2021) (3)
[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]. (2009) (3)
Genitourinary tumors, prostate (2012) (3)
Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients. (2022) (3)
A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). (2011) (3)
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. (2021) (3)
1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT) (2020) (3)
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. (2020) (3)
852PDAtezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study (2017) (3)
[Anti-apoptotic mechanisms in small-cell lung carcinoma]. (2010) (3)
Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both? (2008) (3)
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. (2022) (3)
[Targeting KRAS pathway in NSCLC therapy]. (2009) (3)
The use of tumor growth rate (TGR) in evaluating sorafenib and everolimus treatment in mRCC patients: An integrated analysis of the TARGET and RECORD phase III trials data. (2012) (3)
Reversible cardiogenic shock following 5-Fluorouracil infusion (2010) (3)
7153 POSTER Treatment (trx) Modalities After a Front Line Targeted Therapies in Patients (pts) With Metastatic Renal Cell Carcinoma (mRCC) (2011) (3)
762PDIMPACT OF ENZALUTAMIDE ON SKELETAL RELATED EVENTS (SRES), PAIN AND QUALITY OF LIFE (QOL) IN THE PREVAIL TRIAL. (2014) (3)
285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) (2016) (3)
Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study (2019) (3)
Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor. (2020) (3)
ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). (2018) (2)
Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. (2019) (2)
[Cancer stem cells: a new target for lung cancer treatment]. (2011) (2)
Inhibiting bcl-2 in small cell lung cancer cell lines with oblimersen, an antisense bcl-2 oligodeoxynucleotides (ODN) is an effective strategy to enhance the efficacy of radiation in vitro and in vivo (2007) (2)
34MO Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials (2021) (2)
EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). (2018) (2)
Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011. (2020) (2)
Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder. (2012) (2)
Abstract 5600: Establishment and characterization of a unique circulating tumor cells-derived xenograft (CDX) in prostate cancer (2018) (2)
ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC). (2018) (2)
French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC). (2022) (2)
698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma (2021) (2)
Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): Retrospective experience at Gustave Roussy. (2016) (2)
Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study (2019) (2)
KIT expression in postradiation sarcoma (2009) (2)
Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma. (2016) (2)
P109 Efficacy outcomes by baseline prostate-specific antigen (PSA): Results from the Phase III AFFIRM trial (2013) (2)
Erdafitinib in Urothelial Carcinoma. Reply. (2019) (2)
Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib. (2020) (2)
Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial (2015) (2)
757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status (2020) (2)
[New drugs in metastatic castration-resistant prostate cancer]. (2010) (2)
TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy. (2022) (2)
Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. (2022) (2)
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model (2020) (2)
692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC) (2020) (2)
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. (2009) (2)
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. (2022) (2)
LBA3 Enzalutamide in men with chemotherapy-naïve metastatic castration resistant prostate cancer (MCRPC): Primary and European regional results of the phase 3 prevail study (2014) (2)
Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa). (2018) (2)
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. (2023) (2)
862PTreatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective (2017) (2)
Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT). (2016) (2)
[Molecular aspects of head and neck, and lung cancer oncogenesis]. (2009) (1)
Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL. (2016) (1)
Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer (2021) (1)
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer (2022) (1)
FIGHT against FGF/FGFR alterations: what are the next steps? (2022) (1)
Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma. (2020) (1)
Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: still to be established. (2011) (1)
3010 Prevalence and causes of burnout syndrome among oncology residents in France: a comprehensive cross sectional study (2009) (1)
Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC). (2021) (1)
Impact of bone metastases at initial diagnosis in male patients with metastatic germ cell tumors: Results from an international database (2014) (1)
Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC). (2013) (1)
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy. (2022) (1)
Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial Carcinoma (2017) (1)
The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls (2022) (1)
Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III). (2018) (1)
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. (2012) (1)
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study. (2021) (1)
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology (2022) (1)
WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. (2017) (1)
A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer. (2021) (1)
Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC). (2021) (1)
Long-term tolerance of neoadjuvant docetaxel/estramustine chemotherapy in patients with high-risk localized prostate cancer treated at IGR in the GETUG 12 phase III trial. (2013) (1)
FGFR alterations in urothelial carcinoma: Picking the right target. (2021) (1)
766P Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study (2020) (1)
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test (2022) (1)
7162 Post-chemotherapy residual masses <15 mm in patients with metastatic non seminomatous germ cell tumors: is resection required? (2009) (1)
[Stage 1 germ-cell tumour]. (2019) (1)
7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial (2011) (1)
799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations (2020) (1)
711P Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials (2021) (1)
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2. (2021) (1)
2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (2015) (1)
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study. (2022) (1)
Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study (2019) (1)
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients? (2014) (1)
F01*New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) (2015) (1)
751P Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy (2020) (1)
Abstract 1723: Diagnostic leukapheresis results in a significant increase in CTC yield in metastatic breast and prostate cancer (2017) (1)
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine (2021) (1)
Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d Data From The Prevail Trial. (2015) (1)
Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study (2019) (1)
Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study (2022) (1)
Results of the GETUG-AFU 19 trial: A randomized phase II study of dose dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) with or without anti-epidermal growth factor receptor (EGF-R) monoclonal antibody panitumumab (PANI) in advanced transitional cell carcinoma (ATCC). (2017) (1)
Outcome of patients with rare tumors included in phase l clinical trials. (2010) (1)
2626 Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis (2015) (1)
Use of 18F-FDG PET/CT to select candidates for active surveillance: Results of the SEMITEP trial of PET-directed strategy for stage 1 seminoma. (2018) (1)
The GETUG SEMITEP Trial: De-Escalating Chemotherapy in Good-Risk Metastatic Seminoma Based on Early FDG-PET/CT (2020) (1)
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials (2021) (1)
[DNA damage repair: An emerging strategy in metastatic prostate cancer]. (2018) (1)
Emerging Targeted Therapy for Bladder Cancer. (2021) (1)
Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3–Positive Lymphatic/Vascular Endothelial Progenitor Cells (2009) (1)
Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis. (2020) (1)
["Treatment of bladder cancer with immune checkpoints inhibitors"]. (2021) (1)
Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study) (2018) (1)
Biologic consequences of androgen receptor (AR) activity in MDV3100-resistant LNCaP cells and dependence on AR full length. (2014) (1)
[Management of clinical stage I testicular germ cell tumours]. (2007) (1)
Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee (2022) (1)
Abstract 4891: Radiation enhances the efficacy of Bcl-2 and Bcl-XLinhibition in small cell lung cancer: A new concept of using radiation for targeted therapy through contextual oncogene addiction (2012) (1)
Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157]. (2017) (1)
Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC). (2021) (1)
Skeletal-Related Events (SRES) Impact Significantly the Health-Related Quality of Life (HRQOL) of Chemo-Naive Men With Metastatic Castration Resistant Prostate Cancer (MCRPC). (2014) (1)
PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL (2022) (1)
Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results. (2023) (1)
Abstract 2147: Development of preclinical models to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies (2018) (1)
Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC). (2018) (1)
Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC) (2014) (1)
Ultrasound and Magnetic Resonance Imaging of Burned-Out Testicular Tumours: The Diagnostic Keys Based on 48 Cases (2022) (1)
Abstract 1597: A novel preclinical model of prostate cancer bone metastasis derived from a human primary tumor (2011) (1)
MVP and vinorelbine for malignant pleural mesothelioma (2008) (1)
Resistance to Chemical Castration: Second-Line Hormonal Treatment (2012) (1)
Abstract 3386: Mechanisms of resistance to enzalutamide in LNCaP models. (2013) (1)
Abstract 1114: Novel preclinical models of aggressive variants of castration-resistant prostate cancer (2020) (0)
Gene expression profiling of sequential tumor biopsies is a powerful approach to identify putative biomarkers of therapeutic benefit in a phase I study combining sorafenib and dacarbazine (2007) (0)
Efficacy of treatment beyond third-line (3L) in metastatic clear-cell renal cell carcinoma (mccRCC). (2018) (0)
Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study. (2023) (0)
1142 Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial (2016) (0)
Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer (2022) (0)
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. (2023) (0)
1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011 (2022) (0)
EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France (2022) (0)
[Management of localized germ-cell tumours of the testis]. (2007) (0)
Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC) (2019) (0)
85P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials (2023) (0)
2631 Inclusion of patients with urothelial bladder cancer in phase 1 trials: What is the impact? (2015) (0)
Abstract 4664: MatchR a preclinical platform of models resistant to innovative therapies (2023) (0)
Abstract A192: PK/PD modeling-based optimization of administration schedule for the histone deacetylase inhibitor (HDACi) S78454/PCI-24781 in phase I. (2011) (0)
83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10 (2021) (0)
Abstract 2746: A phase I, dose-escalation study of the Eg5-inhibitor EMD534085 in subjects with advanced solid tumors and lymphoma (2010) (0)
Concordance of plasmatic circulating DNA and matched metastatic tissue in metastatic urothelial carcinoma (2020) (0)
PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC). (2020) (0)
Bone metastases in germ cell tumors: Results from an international data base. (2014) (0)
961P Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience (2020) (0)
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. (2014) (0)
A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC). (2016) (0)
Abstract CT179: ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (2019) (0)
Molecular characterization of heterogeneity in circulating tumor cells (CTCs) and tumor samples of metastatic castration-resistant prostate cancer (mCRPC) patients: The multicenter PETRUS program. (2015) (0)
461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study (2022) (0)
Randomized phase 2 umbrella study of various neoadjuvant therapies for patients with muscle-invasive urothelial carcinoma of the bladder (MIBC) who are cisplatin-ineligible or refuse cisplatin therapy and undergoing radical cystectomy (Optimus). (2022) (0)
Genomic landscape of metastatic platin-resistant urothelial cancer patients. (2015) (0)
Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas (2018) (0)
ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma. (2018) (0)
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer (2016) (0)
Abstract 400: Functional, structural and binding studies of the atypical ER-resident protein FKBP7, a potential target in chemoresistant prostate cancer (2022) (0)
Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8]. (2019) (0)
Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. (2023) (0)
Abstract 358: A prospective study of prostate cancer metastases identifies an androgen receptor activity-low, stemness program associated with resistance to androgen receptor axis inhibitors and unveils mechanisms of clonal evolution (2021) (0)
Regulation of eIF4F complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer (2016) (0)
First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials. (2022) (0)
French AFU Cancer Committee Guidelines - Update 2022-2024: Muscle-Invasive Bladder Cancer (MIBC). (2022) (0)
Abstract P2-13-02: COBRA: Characteristics and Outcomes of patients with BReast cancer in phAse I trials at Gustave Roussy Cancer center (2023) (0)
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) (2021) (0)
981 Should the primary site be treated in patients with de novo metastatic prostate cancer (2014) (0)
638P Meningeal metastases (MM) in patients with metastatic castration resistant prostate cancer (mCRPC) (2020) (0)
A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs) (2019) (0)
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC). (2023) (0)
1165P Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas (2017) (0)
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. (2023) (0)
Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361. (2022) (0)
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A). (2021) (0)
Abstract 1755: Sensitization of radiotherapy and chemotherapy by adjunction of R1507 (anti-IGF-1R monoclonal antibody) in small cell lung cancer cell lines: Opportunity of translating the triple combination R1507-Cisplatin-radiotherapy (2011) (0)
Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC). (2020) (0)
750P Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001) (2020) (0)
1232 Impact of age on the outcome of cancer patients treated in phase I trials between 2005 and 2008 (2009) (0)
A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532). (2023) (0)
7158 POSTER Impact of Targeted Therapies on Muscle Loss and Adipose Tissue in Metastatic Renal Cell Carcinoma (mRCC) (2011) (0)
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC) (2022) (0)
BCG and Anti-PDL-1 Ab in Bladder Cancers (2018) (0)
Abstract 2374: First time identification of circulating tumor cellsin murine models of human non-small cell lung cancer (2011) (0)
A prospective study of carboplatin-etoposide in docetaxel-pretreated patients with hormone-refractory prostate cancer (HRPC): Clinical activity and correlation with neuroendocrine features (2007) (0)
Abstract 3414: Systematic comparison of ctDNA vs tissue sequencing with a large panel to guide therapy in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM) (2022) (0)
Metastatic Germ Cell Tumours (2014) (0)
176P Phase I study of INCB106385 alone or in combination with immunotherapy in advanced solid tumors (2022) (0)
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma (2023) (0)
A comparison of the outcomes after neoadjuvant (NC) or adjuvant chemotherapy (AC) for muscle-invasive urothelial bladder cancer (UC): A French contemporary retrospective multicenter cohort. (2015) (0)
High prevalence of Clonal Hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors (2022) (0)
Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mnccRCC). (2018) (0)
7166 Predicting and preventing thrombo-embolic events in patients with germ-cell tumors receiving cisplatin-based chemotherapy (2009) (0)
PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA (2016) (0)
7020 Performance status and interval from first-line docetaxel-based chemotherapy to progression are significant prognostic factors in patients with castration-resistant prostate cancer receiving second-line chemotherapy (2009) (0)
PD09-10 AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY (2023) (0)
2P Outcomes of patients with gynecological tumors harboring HER2 defects: A single center study based on Gustave Roussy cancer center’s molecular program (2023) (0)
Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (2023) (0)
Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison (2019) (0)
[Guidelines from the cancer (CC-AFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG]. (2022) (0)
1237 Is it ethical to enrol patients with advanced solid tumor in first line therapy in Phase 1 trials (2009) (0)
Abstract 4062: Clusterin downregulation sensitize prostate cancer cells to taxane by modulating mitosis. (2013) (0)
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. (2023) (0)
Twitter as a Medical Media Among French Young Oncologists: Results from a National Survey (2021) (0)
PD-7 Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study (2022) (0)
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors (2023) (0)
Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361. (2022) (0)
34P Gustave Roussy Match-R study: A descriptive analysis of the molecular target population (2022) (0)
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease (2019) (0)
Abstract 2122: Generation of a fully characterized preclinical PDX panel to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies (2019) (0)
Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361. (2021) (0)
Large Molecule Therapeutics IGF-1 R Targeting Increases the Antitumor Effects of DNA-DamagingAgents in SCLCModel : AnOpportunity to Increase the Ef fi cacy of Standard Therapy (2013) (0)
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer? (2015) (0)
Evaluating safety and efficacy of INCB054828 as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma (UC): A phase 2 study of the European Association of Urology Research Foundation (EAU-RF) (2018) (0)
Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). (2023) (0)
Medical therapy for renal cell cancer with pancreatic metastases: Experience of the Gustave Roussy Institute. (2015) (0)
Abstract 3016: Identification of the mechanisms of resistance to targeted therapies in advanced solid cancers (2021) (0)
Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy. (2012) (0)
A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment. (2019) (0)
A phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC) (2021) (0)
Dexamethasone in pretreated men with metastatic castration-resistant prostate cancer (mCRPC): A prospective study. (2018) (0)
826PCONTRIBUTION OF TUMOR BURDEN AND BODY COMPOSITION PARAMETERS AS PROGNOSTIC FACTORS OF METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED BY TARGETED THERAPY. (2014) (0)
1234 Prognosis of patients enrolled in phase I clinical trials admitted in intensive care unit (2009) (0)
Method for semi-automated microscopy of filtration-enriched circulating tumor cells (2016) (0)
Studying Rarity in Bladder Cancer. (2019) (0)
[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer]. (2022) (0)
Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations (2016) (0)
Trial In Progress: DISCUS: A randomized phase II study comparing 3 vs. 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer (2022) (0)
Abstract 3413: Clinical utility of circulating tumor DNA sequencing with a large panel: The experience of Gustave Roussy/National Center for Precision Medicine (PRISM) (2022) (0)
Effect of generation 2.5 antisense inhibitor of androgen receptor on MDV3100-resistant prostate cancer cell growth in vitro and in vivo. (2013) (0)
259 INVITED Bone Targeting (2011) (0)
Thermal ablation for the treatment of bone metastases (BM) in patients (pts) with metastatic renal cell carcinoma (mRCC): Experience from IGR. (2015) (0)
Chapter 2 PSA as a marker of progression and response in advanced prostate cancer (2010) (0)
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. (2023) (0)
105 cases of renal tumors in patients age 15 to 35: A specific entity? Experience of the Gustave Roussy Institute. (2014) (0)
Rechallenge with axtinib in metastatic renal cell carcinoma (mRCC) - Experience from Gustave Roussy (2016) (0)
1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100 (2022) (0)
596 Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration (2015) (0)
748P Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study (2020) (0)
PD55-01 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA IN THE JAVELIN BLADDER 100 TRIAL: SUBGROUP ANALYSIS BY DURATION OF TREATMENT-FREE INTERVAL FROM END OF CHEMOTHERAPY TO START OF MAINTENANCE (2021) (0)
FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib. (2019) (0)
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history. (2023) (0)
1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC) (2021) (0)
Long-term results and prognostic factors for survival following adjuvant chemotherapy (AC) for muscle-invasive urothelial bladder cancer (UC): A French retrospective multicenter cohort. (2014) (0)
Prognostic role of body composition parameters in renal cell carcinoma (RCC). (2012) (0)
TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC). (2023) (0)
Consolidative radiotherapy for metastatic urothelial bladder cancer patients without progression and with no more than three residual metastatic lesions following first line systemic therapy: A prospective randomized comparative phase II trial (BLAD RAD01/GETUG-AFU V07). (2021) (0)
824PDIFFERENCES BETWEEN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WHO DEVELOP BRAIN METASTASES (BM) VERSUS THOSE WHO DO NOT. (2014) (0)
TROPHU-U-01 cohort 5: Evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC). (2023) (0)
[Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC]. (2020) (0)
1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer (2022) (0)
MATCH-R development of preclinical models from patient with acquired resistance to targeted therapy. (2018) (0)
Early replacement of CT scanning by abdomino-pelvic ultrasound as a safe alternative in the follow-up of patients with germ cell tumors. (2017) (0)
Abstract 1929: Establishment, molecular and pharmacological profiling of novel prostate cancer-derived xenografts from patients with advanced, treatment-refractory, disease to identify resistance mechanisms and new therapeutic options (2019) (0)
A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations. (2018) (0)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
116 R1507, a human monoclonal antibody targeting IGF-1R (insulin like growth factor receptor) is effective alone and sensitizes small cell lung cancer cell lines to chemotherapy and radiation in vitro (2010) (0)
Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results. (2023) (0)
282 Set up of a xenogenic, orthotopic and bioluminescent model of localized lung cancer in mice: a stepwise approach (2010) (0)
1168PEstimation of benefice to anti-PD-(L)1 for metastatic patients by real-time quantitative and functional estimation of immune infiltrate with RNAseq (2017) (0)
Profile and Outcome of Cancer Patients enrolled in Contemporary Phase I Trials (2023) (0)
MP41-13 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL (2021) (0)
F24Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): retrospective analysis (2015) (0)
A prospective descriptive 1‐year study in France of all BCG therapy dispensations for non‐muscle‐invasive bladder cancer (2022) (0)
Abstract B26: EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy (2020) (0)
Abstract 2230: Integrative genomic analysis of refractory metastatic cancer (2021) (0)
321 ANTISENSE INHIBITOR TARGETING FULL LENGTH ANDROGEN RECEPTOR AND ITS SPLICE VARIANTS SUPPRESSES MDV3100 RESISTANT PROSTATE CANCER CELL GROWTH (2013) (0)
Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy (2019) (0)
Frequency of liver test increases on abiraterone acetate in men with castrate-resistant prostate cancer (CRPC): Natural history, management, and outcome. (2018) (0)
A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study (2016) (0)
Abstract 3458: Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer (2023) (0)
1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) (2022) (0)
Abstract 4953: Whole-exome sequencing of single circulating tumor cells according to epithelial-mesenchymal marker expression in metastatic prostate cancer (2016) (0)
140P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials, with focus on NSCLC (2023) (0)
Description and prognostic value of the mutational load across various metastatic solid tumors in the prospective MOSCATO-01 and MATCH-R trials (2016) (0)
Safety and efficacy of atezolizumab (atezo) for locally advanced or metastatic urothelial or non-urothelial urinary tract carcinoma: Subgroup analyses of the international SAUL study according to PD-L1 status and age (2019) (0)
41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)? (2023) (0)
129P Molecular screening and early phase trial inclusion for head and neck squamous cell carcinoma patients (2022) (0)
Abstract 3113: Molecular and pharmacological profiling of a novel prostate cancer-derived xenograft panel to identify resistance mechanisms and new therapeutic options (2022) (0)
Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression. (2014) (0)
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate. (2021) (0)
P126 Can we predict which patients with metastatic Renal Cell Carcinoma (mRCC) will develop Brain Metastases (BM) (2014) (0)
Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304. (2023) (0)
French AFU Cancer Committee Guidelines - Update 2022-2024: Upper urinary tract urothelial cancer (UTUC). (2022) (0)
Predictive and prognostic biomarkers for next-generation hormonal agents in castration resistant prostate cancer (2015) (0)
ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (2019) (0)
1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB) (2022) (0)
Genomic characterization of metastatic cisplatin-resistant samples from urothelial cancer patients. (2014) (0)
SAFETY PROFILE OF COMBINATION THERAPY WITH IMMUNE CHECKPOINT BLOCKERS AND VEGF INHIBITORS IN OLDER PATIENTS TREATED IN EARLY PHASE CLINICAL TRIALS (2019) (0)
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). (2023) (0)
Second Line Treatment in Metastatic Papillary Renal Cell Carcinoma: Retrospective Analysis of a 48 Patients Cohort (2012) (0)
Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC). (2019) (0)
Erdafitinib for locally advanced or metastatic urothelial carcinoma (2022) (0)
2513 New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) (2015) (0)
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001) (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yohann Loriot?

Yohann Loriot is affiliated with the following schools:

Paris-Saclay University
University of Alberta
University of British Columbia
Paris Diderot University